The GIP receptor activation adds an entirely separate pathway for metabolic improvement
discontinue if not tolerated after second attempt In patients with type 2 diabetes, monitor blood glucose before initiating and during treatment Once weekly SC dose escalation schedule Weeks 1-4: 0.25 mg Weeks 5-8: 0.5 mg Weeks 9-12: 1 mg Week 13-16: 1.7 mg Week 17 and onward: 2.4 mg (maintenance) Dosage Modifications Renal or hepatic impairment No dosage adjustment required Upper GI tract disease Oral: No dosage adjustment required Dosing Considerations Limitations of use Not studied in patients with a history of pancreatitis Ozempic, Rybelsus (T2DM) Wegovy (weight management) Contains semaglutide and should not be coadministered with other semaglutide-containing products or with any other GLP-1 receptor agonist Safety and effectiveness in combination with other products intended for weight loss, including prescription drugs, OTC drugs, and herbal preparations, have not been established Pediatric: Weight Management Wegovy only Indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in pediatric patients aged 12 years or above with an initial BMI at 95th percentile or higher, standardized for age and sex (obesity) Refer to prescribing information for BMI cut-offs for obesity by sex and age for pediatric patients aged 12 years or above (CDC Criteria) Once weekly SC dose escalation schedule Weeks 1-4: 0.25 mg SC once a week Weeks 5-8: 0.5 mg SC once a week Weeks 9-12: 1 mg SC once a week Week 13-16: 1.7 mg SC once a week Maintenance dosage Week 17 and onward: 2.4 mg SC once a week Unable to tolerate maintenance 2.4 mg once-weekly dosage: May reduce maintenance dosage to 1.7 mg SC once a week Unable to tolerate 1.7 mg-dose: Discontinue treatment Dosage Modifications Renal impairment All severities, including end-stage renal disease: No dosage adjustment necessary Hepatic impairment All severities: No dosage adjustment is necessary Dosing Considerations Limitations of use Wegovy Do NOT combine with other semaglutide-containing products or with any other GLP-1 receptor agonist Safety and effectiveness in combination with other products intended for weight loss, including prescription drugs, OTC drugs, and herbal preparations, not established Not studied in patients with a history of pancreatitis Overdose Semaglutide overdose can cause severe nausea, vomiting, and low blood glucose levels (hypoglycemia)
Ellagitannins are also abundant in other fruits and nuts, such as raspberries and walnuts
Regulators warn about product-quality uncertainty and adverse effects ranging from nausea and flushing to changing pigmented lesions and serious systemic reactions
